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over the period. However, cost of health care remains an important impediment to 
access health care particularly in rural areas.
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A LiterAture review And Micro costing APProAcH to deterMine tHe 
cost of one Hour of oPerAting tiMe in cAnAdA
Goldstein L.J., Ondrejicka D.A.
Johnson and Johnson Medical Companies, Markham, ON, Canada
OBJECTIVES: There is little understanding on the true cost of operating room time in 
Canada despite the fact that surgical care is paid for by a single payer facing increas-
ing cost constraints. The objective of the review was to analyze how OR costs are 
currently conceived of in Canadian hospitals. Additionally, a micro costing approach 
was used to estimate the actual cost using a bottom-up approach. METHODS: A 
literature search was conducted to determine how Canadian hospitals perceived the 
value of one hour of operating time. Studies satisfying the defined criteria were com-
pared in terms of methodology and inclusion and exclusion of specific resources 
in their perception of their institution’s OR expenditure. All costs were adjusted 
to 2014 Canadian dollars. Additionally, we conducted an independent bottom-up 
micro-costing analysis of Canadian operating room time. Completion of the litera-
ture review prior to micro costing ensured a robust and comprehensive approach 
was used. Costs were obtained using peer-reviewed literature and from a large 
Canadian hospital network. RESULTS: Specific search and inclusion criteria resulted 
in the inclusion of 5 studies in our analysis. The cost of OR time ranged greatly 
from $621.60 to $2288.94 per hour. All studies obtained the cost of OR time using a 
top-down case-costing approach informed with data from their respective finance 
departments. Each study was conducted at a different Canadian hospital and OR 
costs were perceived in strikingly different ways. Additionally, many of the studies 
lacked sufficient methodological details providing a challenge when comparing 
approaches. The bottom-up micro case-costing approach incorporated more than 
30 individual costs and resulted in an OR hourly cost of $1200. CONCLUSIONS: In 
Canada, there is little consensus between institutions of how to capture the costs 
of OR time. A bottom-up micro costing approach allowed for a different perspective 
and a more detailed analysis.
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current estiMAtes of tHe PubLic PHArMAceuticAL exPenditure in 
MongoLiA
Dorj G.
Mongolian University of Medical Sciences, Ulaanbaatar, Mongolia
OBJECTIVES: In less developed nations public resources are scarce and medicines 
are often not adequate, nor accessible for much of the population. Only limited 
quantitative data are available for analysis of the pharmaceutical expenditure in 
Mongolia. METHODS: Retrospective data collection on pharmaceutic expenditure 
from government issued reports were collected and analysed for the period of six 
years starting from 2009 until 2014. RESULTS: The gross domestic product (GDP) was 
11.52 billion USD in 2013 in Mongolia and the proportion of total health expenditure 
(THE) was 566.5 billion Mongolian National Tugrug (MNT) or 301.4 million USD. For 
2014, the total pharmaceutical expenditure (TPE) was 81.3 billion MNT or 11.6% of 
the THE. The public pharmaceutical expenditure (PPE) per capita was 28727.9 MNT 
or 15.3 USD in 2013. Mongolia is a developing country and the public expenditure on 
pharmaceuticals per capita was in the mid-range of developing country expenditure. 
The funding source of pharmaceuticals in Mongolia was analysed and the external 
source played a minimal role for TPE (4.8%) whereas government sourced fund (tax) 
was the highest (80.4%). Currently, no data are available on private health funds 
in Mongolia. Previous findings reported that out-of-pocket payments for health 
service has increased from 14.5% of the THE in 1995 to 41.4% in 2010. However, 
data in regards to out-of-pocket payment for pharmaceuticals were not availa-
ble. CONCLUSIONS: This study provided country specific estimates of expenditure 
funded by public source at the national level in regards with total pharmaceutical 
expenditure and per capita. in addition, data on private funding for pharmaceuticals 
are required in order to conduct the specific policy analyses including different cost 
items, equity of access, allocative efficiency, therapeutic and operation efficiency. 
However, the results of this review can be used as a baseline for monitoring future 
trends in pharmaceutical expenditure over time in Mongolia.
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HeALtH AreA
Hernandez-Villafuerte K., Sussex J.
Office of Health Economics, London, UK
OBJECTIVES: The cost-effectiveness threshold applied in the process of recom-
mendation of new health technologies is a central topic of discussion in the UK. A 
key element in the discussions is the marginal effect that a change on the health 
expenditure has on mortality per health category; since this is an indication of the 
opportunity cost of adopting a new technology. The common assumption is that all 
health areas behave in roughly the same way as each other when faced with a cut 
in available funds. This suggests that the opportunity cost, and consequently the 
threshold value, is the same regardless health area. This overlooks potential dif-
ferences between health areas (e.g. the way in which health services are provided 
in different localities). If there are such differences then different health areas will 
be producing health gain in different ways, and will produce different health gains 
per pound spent. The primary aim of this study is to test the assumption that 
health areas are similar to one another in the decisions they make. METHODS: 
We applied the Cluster Analysis Methodology. We propose a division in which the 
health areas within one cluster are those that are similar to each other in terms 
of the expenditures (adjusted by costs differences and needs) allocated to each 
health categories. Four clusters partitions are estimated, each one based on a dif-
ferent year. By doing this, we are able to compare the composition of the different 
groups over time. RESULTS: The data indicates that some health areas spent dif-
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PubLisHed costs of MedicAtion errors LeAding to PreventAbLe 
Adverse drug events in us HosPitALs
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OBJECTIVES: Medication errors (ME) are defined as any preventable event that may 
cause or lead to inappropriate medication use or patient harm. ME are garnering 
national attention as evidenced by the National Action Plan for Adverse Drug Event 
Prevention to drive prevention strategies for high-risk drug classes. We sought to 
understand the economic burden of ME that lead to preventable adverse drug events 
(pADEs) in US hospitals. METHODS: From a broader literature review on inject-
able ME in Medline and Embase (2003-2014), we identified eleven articles related 
to the incidence and economic impact of pADEs arising from all ME. A supplemen-
tal PubMed search identified four additional articles dating back to 1995. All cost 
estimates were converted into 2014 dollars. RESULTS: Published estimates of ME 
cost varied based on population, setting of care, methodology and study period. 
Three studies estimated the annual cost of pADEs for the inpatient setting at the 
national level. A 1999 study estimated that annual national costs of pADEs were 
$4.8 billion, while a 2012 study showed that injectable-related pADEs alone cost 
$2.8-5.2 billion. For Medicare beneficiaries, pADEs cost $617 million annually. At the 
individual hospital level, the total annual cost of pADEs ranged from $0.9 to $5.6 
million. Costs per individual pADE differed based on severity, and ranged from $3408 
to $6931. Key cost drivers included increased length of stay, additional laboratory 
testing, routine care, surgical, and other ancillary charges. CONCLUSIONS: This 
literature review highlights the economic burden of ME in the US. Cost estimates 
varied considerably due to different definitions, study methodologies, and analytic 
scope. Given the emergence of pADE harm reduction as a national priority, there is 
a need for updated research aimed at evaluating the economic impact of medica-
tion errors using standardized definitions for types of errors, their severity and the 
ensuing financial impact.
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tHe finAnciAL iMPAct of bLood sPeciMen rejection due to tHe Poor 
Pre-AnALyticAL QuALity in HeALtHcAre fAciLity in cHinA
Liu Y.1, Ren X.2
1Shenyang Pharmaceutical University, Shenyang, China, 2BD China, Shanghai, China
OBJECTIVES: To quantify the financial impact of poor blood specimen quality on 
treatment and hospital costs in a healthcare facility in China, using institution 
specific data. METHODS: The data were collected from six hospitals (beds≥ 500) in 
Beijing, Shanghai and Guangzhou by interviewing institution staff, including opera-
tional data such as total operating costs, medical treatment data such as probability 
of a low, medium or high impact of a rejection, laboratory data such as total number 
of blood tests. The patients were divided into three categories: critical inpatients, 
routine outpatients, and elective surgery inpatients, since the costs of an error vary 
greatly among the three categories. Finally, the data were entered into a model to 
calculate the possible financial impact of blood specimen rejection. RESULTS: The 
estimated average costs of a blood specimen rejection were $56, $250 for critical 
inpatient, $31 for other inpatient, and $39 for outpatient, respectively. On average, 
pre-analytical specimen error costs were $494, 422, accounting for 0.12% of total hos-
pital operational costs. The impact of errors on efficiency can be assessed by hours 
lost, there is an estimated 16,913 total patient hours was lost in one year, equaling 
to short of 4029 patients treatment. 3.62% (612) of hours lost was due to laboratory 
redraw and retest, and 96.38%(16,301) was due to patient treatment. In a healthcare 
facility, patient treatment costs represent the largest cost category at 92.18%, redraw 
costs at 3.21%, instrument downtime costs at 2.99%, lab investigation costs at 1.57%, 
and blood collection consumables at 0.05%. CONCLUSIONS: Blood specimen rejec-
tions due to the poor pre-analytical quality increase operational costs and decrease 
the efficiency of hospitals, healthcare facility should monitor pre-analytical blood 
processes and use high-quality device to decrease pre-analytical errors.
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Jahangeer R.A.
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OBJECTIVES: This analysis investigates regional variation in catastrophic health 
care spending in Pakistan. METHODS: The study draws data from three rounds 
of Pakistan Living Standards Measurement Survey (PLSM) conducted in both rural 
and urban areas of Pakistan in 2005-06, 2007-08 and 2010-11. A household is clas-
sified as incurring catastrophic health expenditure if 10% or more of its annual 
expenditure is on health care. Household economic status is measured using house-
hold annual consumption expenditures and households are categorized into quin-
tiles. RESULTS: The proportion of households incurring catastrophic health care 
expenditure has declined from 7.5% in 2005-06 to 3.2% in 2010-11. The decline has 
been slightly more in case of rural households than in urban (4.9% urban and 9.1% 
rural households in 2005-06 vs. 2.0% urban and 3.8% rural households in 2010-11 
incurred catastrophic health care spending. Of poorest households, 7.5% incurred 
catastrophic health expenditure in 2005-06, 5.4% in 2007-08 and 3.5% in 2010-11 
whereas, of richest, the proportion was 6.2%, 5.4% and 2.7% for respective periods. 
Further, significantly more households in Punjab are incurring catastrophic health 
care expenditure compared to Sindh. There is regional variation across regions 
and remarkable decline in catastrophic health care spending. South Punjab had 
the highest proportion (13.6%) while south Sindh had lowest proportion (2.4%) of 
households incurring health care expenditure in 2005-06. South Sindh still has the 
lowest proportion (0.4%) whereas, north Punjab replaces south Punjab having the 
highest proportion (5.4%) of households incurring catastrophic health expenditure 
in 2010-11. CONCLUSIONS: Pakistan has registered a decline in catastrophic health 
care spending over the period. It could be associated with a decline in morbidity 
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expanded services and mandating quality. Studies show that wellness programs are 
growing in number and in various sizes, services, and incentives resulting in a signif-
icant to non-significant return-on-investment (ROI). Few employers have measured 
the ROI and even fewer their health outcomes. However, successful programs have 
shown a median ROI between 2:1 and 3:1. Studies suggest that disease-management 
services account for significantly positive ROI while lifestyle management services 
do not. For example, the partnership between Piedmont and WellStar of Georgia 
supported implementation of care-management programs, with higher quality at 
lower costs. CONCLUSIONS: Although most are not reporting ROI, studies show the 
value of wellness programs should be based on health outcomes.
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iMPAct of cLinicAL And HeALtH econoMic PubLicAtions on 
coMMerciAL success of PHArMAceuticAL Products in tHe u.s
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1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Washington, 
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OBJECTIVES: The study objective was to estimate the causal effect of the publication 
of drug-specific clinical and health economic and outcomes research (HEOR) publica-
tions on US drug product sales. METHODS: Quarterly sales data for twenty-two drugs, 
(biologics for rheumatoid arthritis (RA), new generation asthma drugs and statins) 
and contemporaneous publication counts of HEOR, clinical and meta-analytic stud-
ies via literature search were analyzed. Clinical studies were categorized by journal 
impact factor. The total analysis period spanned 2003-2013, with drug-specific expo-
sure varying based on its branded status over that timeframe. Covariates included 
generic availability, safety warnings, and new indications (as a proxy for sales effort). 
First difference and difference in first difference fixed effects models were used to 
control for unobserved time invariant and constant-rate time-variant unobserved 
confounders and estimate the causal effect of an additional study in a given quarter 
and the increase in sales in the next quarter. RESULTS: In the statin market, the 
potential casual effect of an HEOR study publication on next quarter’s sales was 
$1 - $2.2 million. High-impact clinical publication also significantly increased sales 
in the next quarter (~$7 million). In RA and asthma markets, HEOR studies were not 
statistically linked to quarterly sales, but high-impact clinical studies were found 
to have significant effects on asthma drug sales in the next quarter (~$7.5 million). 
Meta-analyses were only found to have a significant effect on RA drugs sales (~$3.5 
million). CONCLUSIONS: Impact of publications on sales varied. Both HEOR and high-
impact clinical studies were associated with an increase in quarterly sales in the 
statin market, where generic competition is high. These effects were seen to a lesser 
degree in the statin and RA markets, where generic competition is lower. Market 
characteristics that vary across the studied classes, such as branded and generic 
competition, may dictate returns from HEOR and clinical studies.
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PrevALence of MedicAtion use not cAPtured by PrescriPtion cLAiMs 
dAtAbAses â€ “ An AnALysis using 2012 MedicAL exPenditure PAneL 
survey dAtA
Electricwala B.1, Carroll N.V.2
1Virginia Commonwealth University, Richmond, VA, USA, 2Virginia Commonwealth University, 
Richmond, VA, USA
OBJECTIVES: Prescription claims databases are used for identifying patients for dis-
ease management programs and studying health outcomes. The growth in the use 
of drug samples and discount generic programs suggests that an increasing number 
of prescriptions dispensed to insured consumers may not be captured on claims 
databases. We examined the extent to which prescription claims databases do not 
provide complete records of insured patients’ drug use and report the top 5 drug 
classes that were dispensed as drug samples and discount generics. METHODS: We 
used the 2012 Medical Expenditure Panel Survey (MEPS) dataset. We included par-
ticipants who purchased at least one prescription medication and had prescription 
drug insurance for 2012. We quantified the extent to which insured patients used 
drug samples and/or discount generics. We reported descriptive statistics. We used 
Enhanced Therapeutic Classification (ETC) codes to report the top 5 drug classes that 
were dispensed as drug samples and discount generics. RESULTS: A total of 78.6% of 
the U.S. non-institutionalized civilian population was insured for prescription drugs. 
Of the total number of prescriptions dispensed to insured consumers, at least 0.5% 
were drug samples and 4.8% were potentially discount generics. Additionally, 8% of 
insured consumers received at least one sample medication and 21.5% used at least 
one potential discount generic product. The top 5 drug classes dispensed as drug 
samples in descending order were statins, Angiotensin Converting Enzyme (ACE) 
inhibitors, beta-blockers (cardiac selective), Selective Serotonin Reuptake Inhibitors 
(SSRIs) and Proton Pump Inhibitors (PPIs). The top 5 drug classes dispensed as dis-
count generics in descending order were statins, ACE inhibitors, SSRIs, beta-blockers 
(cardiac selective) and PPIs. CONCLUSIONS: Our results indicate that drug samples 
do not contribute substantially to the problem of missing prescription data on claims 
databases. A substantial number of prescriptions that are discount generics may be 
missing from these databases.
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OBJECTIVES: While all pharmaceutical organizations are held accountable for dis-
seminating scientific literature supporting their product’s health economics and 
outcomes (HEOR) data, it is not known whether professionals in HEOR agree on the 
quality of materials being disseminated; nor do we know how often these documents 
are developed internally or outsourced. Therefore, the objective of this study was to 
assess the perceived level of quality of the materials as well as who is developing the 
ferent amounts per health category even after adjusting for population size and 
needs. CONCLUSIONS: The cluster analysis indicates that the health areas cannot 
be considered to behave similarly to one another, since there is more than one 
cluster in each year and the clusters are stable over time.
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1China Health Insurance Research Association, Beijing, China, 2Beijing Brainpower Pharma 
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OBJECTIVES: The objective is to provide data support for government decision-
making by having a general view of the status of disease composition, patient 
flow and use of drug and treatment of inpatients with basic medical insurance in 
cities and towns based on sample survey on the medical service utilization and 
payment of such inpatients from 2010 to 2012. METHODS: Sort all patients by 
the time of being released, according to systematic sampling method, extract a 
certain proportion of the insured patients’ hospitalizing information in sampling 
area. Then project the sample data to the country. Retrospective study using SQL 
server and related software. RESULTS: Total hospitalization expenses under urban 
basic medical insurance increased every year, reaching RMB425.3 billion in 2012, 
got 67.77% increase compared with 2010. Expenses increased primarily due to the 
growth of person-time in receiving treatment. The patient-time in receiving treat-
ment reached 4945 times in 2012, 57.18% increases over 2010. In 2012 the average 
hospitalization expenses amounted to RMB8,601, an increase of 6.75% compared 
with RMB8,057 in 2010. Diseases in circulatory, respiratory, and digestive system 
as well as tumor remain the top four most afflicted, accounting for about 60% of 
the total inpatient population. In the disease sub-category, the three most com-
mon diseases accounted for more than 20% of total diseases in patient-times. 
Due to strengthened clinical management of antibiotics use, expense of systimic 
anti-biotics decreased year by year, with 22.46% in 2012, significantly lower than 
28.99% in 2010. CONCLUSIONS: With the establishment and improvement of 
national health insurance, the needs for medical service of insured patients were 
met with substantive effect, but the resulting pressure on fund spending should 
be given more attention. With the continuous attention to the rational clinical 
treatment, irrationality of clinical medication use has improved, but there still 
remains room to improve.
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wHicH diseAses Are driving tHe increAse in sPending for tHe 
PrivAteLy insured PoPuLAtion of tHe us?
Marder W.D., Huse D.M.
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OBJECTIVES: This study examines disease-specific spending across the full range 
of conditions to identify which conditions are driving the growth in overall spend-
ing in recent years. METHODS: Truven Health MarketScan data for 8M employees 
and their dependents in FFS plans in 2007 and 12M in 2012 are analyzed. The 
samples were weighted to reflect the demographic composition of all US employer 
health plans in those years (as captured by the US Medical Expenditure Panel 
Survey). Total health care spending for each patient was allocated across diseases 
using the Medical Episode Grouper (MEG). MEG allocates the 16,000 ICD9 diagno-
sis codes into 572 conditions. Drug spending is assigned to conditions based on 
clinical logic. Adjudicated payments were summed for each episode type that a 
patient experienced. Analysis focused on absolute change in level of per member 
per year (PMPY) spending (total and out-of-pocket) from 2007 to 2012. We exam-
ined the contributions of disease prevalence and cost per case. RESULTS: PMPY 
spending grew 3.8% per year between 2007 and 2012. Hospital outpatient spending 
grew faster (5.9%) than other settings and prescription drug spending was lower 
(1.7%). The top 10 conditions account for 32% of all spending growth. Preventive 
health services drove up spending by $73 PMPY and was the number 1 driver of 
increased spending. Deliveries, both vaginal and Cesarean Section were in the top 
10. So too were four conditions where obesity is an aggravating factor. Cost per 
case was much more of growth driver than changes in treated prevalence. 2013 
results will be available for presentation. CONCLUSIONS: Administrative data 
when handled carefully can provide a broad overview of changing healthcare 
landscape. The modest cost growth for this population has been widely shared 
across many conditions.
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OBJECTIVES: The Affordable Care Act (ACA) initiated healthcare reforms that stress 
“triple aim” goals: improving patient care, population health, and reducing costs. 
Hospitals are forming mergers and have expanded their employee health and 
wellness programs. The objectives are to (1) summarize the literature on mergers, 
health outcomes, and cost-containment (2) describe value for money of health and 
wellness programs, and (3) provide examples of successful mergers. METHODS: A 
systematic review was conducted to identify the costs and benefits of mergers and 
wellness programs. Articles after 2008 were compiled using search engines PubMed, 
Galileo, Ebscohost, and Google Scholar. Key terms were “value for money”, “corpo-
rate”, “health and wellness program”, “health plan”, “insurance plan”, “hospital”, 
and “merger.” Exclusion criteria were articles involving forms of consolidation and 
wellness programs not tied to insurance plans and without reported costs and/or 
health outcomes. RESULTS: A total of 29 relevant articles were retrieved. Findings 
revealed mergers prevent hospitals from trading-off quality and services for cost 
reductions. However, studies suggest that anticompetitive effects of mergers will 
increase costs. Before the ACA, employers had wellness programs that were not 
standardized. The ACA encouraged improvement of these programs by funding 
